• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

EU to review studies linking Novo Nordisk’s Ozempic to rare eye condition

by December 18, 2024
written by December 18, 2024

Investing.com — The European Medicines Agency (EMA), the European Union’s drug regulator, has announced a review of two scientific studies that suggest a connection between Novo Nordisk (NYSE:NVO)’s popular diabetes drug, Ozempic, and a rare eye condition.

The condition, known as nonarteritic anterior ischemic optic neuropathy, is caused by a loss of blood flow to the optic nerve, leading to vision loss.

The studies, conducted by the University of Southern Denmark, indicate that patients using Ozempic may have an elevated risk of developing this eye condition. In response to these findings, Novo Nordisk has stated that it takes all reports of adverse events from the use of its medicines seriously.

The Danish pharmaceutical company also pointed out that the studies did not establish a direct cause-and-effect relationship between the key ingredient in Ozempic, semaglutide, and the eye condition. Semaglutide is also used in Wegovy, another Novo Nordisk product intended for weight loss.

Novo Nordisk’s internal safety assessment and review of the research studies concluded that the benefit-risk profile of semaglutide remains unchanged, according to the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Birkenstock’s quarterly revenue beats on resilient demand
next post
US House speaker defends stopgap spending as some Republicans, Musk balk

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Trump implies government could cut contracts and subsidies to Musk’s companies

      June 7, 2025
    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 5, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (505)
    • Stock (6,426)

    Latest News

    • Trump implies government could cut contracts and subsidies to Musk’s companies
    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

    Popular News

    • TSMC revenue surges 34% in Nov, but slows from prior month
    • Colombia requires $12 billion budget adjustment to comply with fiscal rule-committee

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy